LFWD

Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support continued commercial execution HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today reported financial results for the second quarter ended June 30, 2026. Corporate & Financial Highlights Revenue increased 16% to $6.6 million in the second quarter of 2026 compared to the second quarter of 2025, marking the strongest quarterly revenue performance since the fourth quarter of 2024. The increase reflects continued execution of Lifeward's commercial strategy and growing adoption across the Company's rehabilitation portfolio. Strengthened the Company's balance sheet to a proforma cash balance of approximately $11 million. The Company had a cash balance of $9.4 million as of June 30, 2026. Through a strategic financing closed on July 6, 2026, providing up to $11.2 million in growth capital, Lifeward raised approximately $5.6 million, $4.1 million of which was received during the second quarter, and $1.5 million was received in July. An additional approximately $5.6 million is available upon achieving either a 150% increase in ReWalk sales or the Company's common stock trading at $13.80 or higher for ten consecutive trading days. Continued successful execution of Lifeward's capital-efficient distribution strategy, expanding patient access through established rehabilitation and durable medical equipment distribution partners while building scalable commercial infrastructure designed to support portfolio growth. In August 2026, Lifeward launched a pilot program with Ottobock Care, a leading U.S. mobility technology patient care organization with more than 50 patient clinics nationwide, broadening access to ReWalk Personal Exoskeleton across the country. Further strengthened Lifeward's restorative healthcare platform, with ongoing investigational device development, combining market-leading rehabilitation technologies with an established reimbursement infrastructure. Advanced the ORMD-0801 oral insulin clinical program, with preparations ongoing for the planned Phase 2 U.S. clinical trial. Clinical development activities continue to be managed by Oramed under the strategic collaboration utilizing funds from the Oratech acquisition. Board composition. Effective August 13, 2026, the Company’s Chairman of the Board Bob Marshall and Directors Mike Swinford and William Sigsbee have decided to step down from the board. The Company extends its gratitude to each of Messrs. Marshall, Swinford and Sigsbee for their service and lasting contributions to the Company. Executive transition. The Company’s Chief Financial Officer, Almog Adar, has decided to depart the Company effective September 30, 2026, and will assist with a transition period to his successor. The Company extends its gratitude to Mr. Adar for his service and lasting contributions to the Company. “The second quarter marks another important milestone in Lifeward's transformation into a scaled restorative healthcare company, with revenue growth demonstrating that the strategy we have implemented is working,” said Mark Grant, President and Chief Executive Officer of Lifeward. “Backed by a strong sales pipeline, we expect this revenue momentum to continue in the second half of 2026.” “Over the past year, we have strengthened Lifeward’s restorative healthcare platform, which includes multiple commercial products, a strong reimbursement infrastructure, a scalable capital-efficient distribution model and an exciting pipeline of potential future rehabilitation technologies. These capabilities create a powerful foundation that we believe will support sustainable long-term growth and expand access to life-changing technologies for patients around the world.” “As part of the governance changes announced today, I am proud of what our team has accomplished together with the support and guidance of our board. We have established the strategy, strengthened the balance sheet, built the commercial infrastructure and positioned the Company to capitalize on significant opportunities ahead.” Second Quarter 2026 Financial Results Revenue increased 16% to $6.6 million in the second quarter of 2026, compared to $5.7 million in the second quarter of 2025. The $0.9 million increase was driven by a 13% increase in ReWalk Personal exoskeletons sales to $2.5 million in the second quarter of 2026 compared to the same period in 2025, primarily reflecting stronger sales in Europe, and AlterG products and services which increased 25% to $4.1 million from the same period in 2025, primarily reflecting higher U.S. unit shipments, service revenue and average selling prices. MyoCycle FES bike sales were $0.1 million, unchanged from the second quarter of 2025. Gross margin was 41% during the second quarter of 2026, compared to 44% in the second quarter of 2025. The year-over-year decrease was primarily due to higher tariffs, fluctuations in foreign exchange rates, and a 4% revenue sharing expense associated with the Oramed transaction. Total operating expenses in the second quarter of 2026 declined 24% to $6.9 million, compared to $9.1 million in the second quarter of 2025, primarily due to $2.8 million of one-time impairment charges recorded in the prior-year period. Excluding these charges, the year-over-year increase primarily reflected higher research and development expenses, including $0.7 million in Oratech clinical trial costs, partially offset by lower sales and marketing and general and administrative expenses. On a non-GAAP basis, which excludes the items listed in the attached non-GAAP reconciliation table, adjusted operating expenses increased by 8% to $6.5 million in the second quarter of 2026, compared to $6.0 million in the second quarter of 2025, with the year-over-year change primarily attributable to $0.7 million in Oratech clinical trial costs. Operating loss declined by 37% in the second quarter of 2026 to $4.2 million, compared to $6.6 million in the second quarter of 2025, primarily due to $2.8 million of impairment charges recorded in the second quarter of 2025 and lower sales and marketing and general and administrative expenses, partially offset by $0.7 million in Oratech clinical trial costs in the second quarter of 2026. On a non-GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted operating loss was $3.8 million in the second quarter of 2026, compared to $3.5 million in the second quarter of 2025, with the year-over-year change primarily attributable to $0.7 million in Oratech clinical trial costs, partially offset by continued operating efficiencies, particularly in sales and marketing and general and administrative expenses. Net loss was $11.5 million, or $4.12 per share, in the second quarter of 2026, compared to $6.6 million, or $7.01 per share, in the second quarter of 2025. Net loss increased by $4.9 million primarily due to non-cash fair value charges in warrant and derivative liabilities, compared to the three months ended June 30, 2025. On a non-GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted net loss was $4.1 million in the second quarter of 2026, compared to $3.5 million in the second quarter of 2025, with the year-over-year change primarily attributable to $0.7 million in Oratech clinical trial costs. Liquidity As of June 30, 2026, Lifeward had $9.4 million in unrestricted cash and cash equivalents, compared to $2.2 million as of December 31, 2025. The proforma cash balance is approximately $11 million, inclusive of $1.5 million in proceeds from the July 6, 2026 capital raise of $5.6 million, $4.1 million of which was received prior to June 30, 2026. About Lifeward Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton, AlterG® Anti-Gravity system, MyoCycle® FES System, and ReStore® Exo-Suit. These solutions span the continuum of care in physical rehabilitation and recovery, deploying the most advanced robotics and AI technologies to restore full health and quality of life to a broadening patient population. The Company is now executing a strategic evolution into a diversified biomedical company, expanding beyond rehabilitation and into high-value therapeutic platforms. This includes its Protein Oral Delivery (POD™) platform, designed to enable oral delivery of biologic drugs, with lead candidate ORMD-0801 (oral insulin) targeting a large and underserved diabetes market. Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com. Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates. Forward-Looking StatementsIn addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: management’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the future operations of Lifeward, including research and development activities; the nature, strategy and focus of Lifeward; Lifeward’s ability to successfully integrate Oratech Pharmaceuticals Ltd. into its organization and realize the anticipated benefits therefrom; anticipated clinical drug development activities and related timelines, and other clinical results; the sufficiency of post-transaction resources to support the advancement of Lifeward’s pipeline through certain milestones and the time period over which Lifeward’s post-transaction capital resources will be sufficient to fund its anticipated operations; unexpected costs, charges or expenses resulting from the strategic transaction; expected timing and results of the ORMD-0801 clinical trial; legislative, regulatory, political and economic developments; the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company’s ability to continue to operate as a going concern; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the ability of a refreshed Board of Directors to effectively oversee and manage the Company and execute its strategy; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2025 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. Contact:Almog AdarChief Financial OfficerLifeward E: [email protected]: [email protected]

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its second quarter 2026 financial results on Friday, August 14, 2026. A press release will be issued and quarterly report will be filed with the SEC prior to 9:30 a.m. ET. The Company will not conduct a conference call. About Lifeward Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton, AlterG® Anti-Gravity system, MyoCycle® FES System, and ReStore® Exo-Suit. These solutions span the continuum of care in physical rehabilitation and recovery, deploying the most advanced robotics and AI technologies to restore full health and quality of life to a broadening patient population. The Company is now executing a strategic evolution into a diversified biomedical company, expanding beyond rehabilitation and into high-value therapeutic platforms. This includes its Protein Oral Delivery (POD™) platform, designed to enable oral delivery of biologic drugs, with lead candidate ORMD-0801 (oral insulin) targeting a large and underserved diabetes market. Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com. Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates. Forward-Looking StatementsIn addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: management’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the future operations of Lifeward, including research and development activities; the nature, strategy and focus of Lifeward; Lifeward’s ability to successfully integrate Oratech Pharmaceuticals Ltd. into its organization and realize the anticipated benefits therefrom; anticipated clinical drug development activities and related timelines, and other clinical results; the sufficiency of post-transaction resources to support the advancement of Lifeward’s pipeline through certain milestones and the time period over which Lifeward’s post-transaction capital resources will be sufficient to fund its anticipated operations; unexpected costs, charges or expenses resulting from the strategic transaction; expected timing and results of the ORMD-0801 clinical trial; legislative, regulatory, political and economic developments; the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company’s ability to continue to operate as a going concern; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2025 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. Contact:Almog AdarChief Financial OfficerLifeward E: [email protected]: [email protected]

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Completed the acquisition of Oratech, transforming into a diversified biomedical innovation company while maintaining a core focus on neurorehabilitation. The Oratech transaction provides a 'meaningful option' on oral protein delivery technology with minimal near-term operational burden as clinical management remains with Oramed. Revenue decline in Q1 was primarily driven by temporary AlterG shipment disruptions caused by working capital constraints and supply chain execution issues. ReWalk personal exoskeleton sales grew 11% year-over-year, supported by expanded distribution and improved reimbursement access through major Medicare Advantage insurers. Gross margin compression to 34.2% resulted from lower manufacturing absorption, higher freight costs, tariffs, and unfavorable foreign currency movements. Successfully transitioned manufacturing from California to a contract manufacturer in Massachusetts, a move that contributed to temporary timing issues but supports long-term scalability. Management expects 2026 total revenue to be similar to 2025, with a stronger exit trajectory in the latter half of the year as backlogs are cleared. Anticipates resolving AlterG supply chain issues across Q2 and Q3, with the business expected to become 'whole' by the end of the third quarter. The $10 million convertible note financing and $6.5 million from the Oratech acquisition significantly strengthened the balance sheet to support operating flexibility. Strategic shift toward a channel partner model (e.g., Verita Neuro, CorLife) is intended to reach patients more efficiently than direct-to-consumer efforts. Development is underway for a newly acquired upper-body exoskeleton targeting 4.6 million stroke survivors, intended to complement the existing ReWalk platform. Recorded a one-time $4.9 million non-cash R&D expense related to the intellectual property acquired in the Oratech transaction. Adjusted operating expenses (non-GAAP) decreased 12% to $5.9 million, reflecting improved productivity and reduced R&D spending on completed programs. Cash used in operating activities declined by 33%, signaling improved operational efficiency and disciplined working capital management. Tariffs and foreign exchange fluctuations accounted for approximately 75% to 85% of the year-over-year gross margin gap. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management confirmed that Q1 shortfalls were timing-related and expects to bridge the gap over the next two quarters. The company has a secured backlog of orders and expects the exit trajectory of 2026 to be better than the entry trajectory. Lifeward is focusing on moving products into the payer landscape, specifically targeting 'the blues' and other private payers following recent wins with Aetna and UnitedHealthcare. The strategy involves utilizing channel partners who have deeper existing relationships with payers to accelerate market access. Management clarified that the Oratech oral insulin program is pre-funded and managed by Oramed, requiring only strategic oversight from Lifeward's CEO. The company aims to be an 'aggregator and exploiter of commercial models,' focusing on innovation while letting partners handle patient identification.

This article first appeared on GuruFocus. Revenue: $3.9 million for Q1 2026, down from $5 million in Q1 2025. ReWalk Personal Exoskeleton Revenue: Increased 11% year-over-year to $1.6 million. Gross Margin: 34.2%, down from 42.2% in the prior year quarter. Total Operating Expenses: $11.7 million, including a one-time non-cash R&D expense of $4.9 million. Adjusted Operating Expenses: Declined 12% to $5.9 million from $6.8 million in Q1 2025. GAAP Operating Loss: Increased to $10.3 million due to one-time expenses. Adjusted Operating Loss: Unchanged year-over-year at $4.6 million. Cash Used in Operating Activities: Declined by 33% to $3.7 million. Unrestricted Cash and Cash Equivalents: $11.4 million at the end of Q1 2026, up from $2.2 million at year-end 2025. Warning! GuruFocus has detected 6 Warning Signs with LFWD. Is LFWD fairly valued? Test your thesis with our free DCF calculator. Release Date: May 15, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Lifeward Ltd (NASDAQ:LFWD) successfully completed the acquisition of Auratech, strengthening its position in biomedical innovation. The acquisition provides access to the Protein Oral Delivery Platform, potentially transformative for various therapeutic indications. Lifeward Ltd (NASDAQ:LFWD) secured $10 million from convertible note financing, significantly strengthening its balance sheet. ReWalk personal exoskeleton sales increased by 11% year-over-year, indicating growth in international sales and reimbursement. The company is expanding distribution and reimbursement access for its neuro-rehabilitation portfolio, including through major insurers like Aetna and Humana. Total revenue for the first quarter decreased to $3.9 million from $5 million in the previous year, primarily due to supply chain constraints. Gross margin declined to 34.2% from 42.2% in the prior year, affected by lower manufacturing absorption and higher expenses. Operating expenses increased to $11.7 million, driven by a one-time non-cash R&D expense related to the Auratech acquisition. The company faced temporary timing disruptions in shipments due to working capital constraints and manufacturing transitions. GAAP operating loss increased to $10.3 million, primarily due to one-time expenses related to the Auratech transaction. Q: Given the shipment timing issues in Q1, should we expect revenue levels to return to last year's levels in Q2 and Q3? A: Yes, it's a fair assumption that revenue levels will bridge across the second and third quarters to match last year's levels. The manufacturing move and cash constraints caused timing issues, but we expect an improved trajectory as the year progresses. - Mark Grant, President, Chief Executive Officer Q: Can you provide more details on the revenue growth in Germany and the U.S. for the ReWalk unit? A: ReWalk revenues in Germany increased by almost 25% quarter-over-quarter, contributing to an overall 11% increase in ReWalk revenues, reaching $1.6 million compared to $1.3 million in the prior year quarter. - Almog Adar, Chief Financial Officer Q: What is the status of the Alter-Z supply and working capital issues, and how will they affect product flow in Q2 and Q3? A: The issues are primarily due to cash constraints and procurement timing. We expect to resolve these as we exit Q2 and move into Q3, although some issues may carry over. We have a backlog of Alter-Z sales that should gain momentum. - Mark Grant, President, Chief Executive Officer Q: How much of the gross margin decline is due to tariffs, FX, and volume absorption? A: Approximately 75% to 85% of the gross margin decline is due to fluctuations in exchange rates and tariffs, with the remainder attributed to production volume absorption issues. - Almog Adar, Chief Financial Officer Q: How are you managing resources with the addition of new products and strategic changes? A: The AuraTech transaction requires minimal resources from our staff, allowing us to focus on commercialization and partnerships. We aim to leverage channel partners to reach patients effectively, aligning with my experience in managing revenue cycles and payer landscapes. - Mark Grant, President, Chief Executive Officer For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Image source: The Motley Fool. Friday, May 15, 2026 at 8:30 a.m. ET Chief Executive Officer — William Grant Chief Financial Officer — Almog Adar William Grant: Thank you, Almog, and thank you for everybody for joining us today. The first quarter of 2026 marked an important strategic milestone for Lifeward as we successfully completed the acquisition of Oratech. We believe this transaction significantly strengthens Lifeward's position as a diversified biomedical innovation company while reinforcing our focus on neurorehabilitation and our path toward profitability. We believe this was a highly strategic and capital-efficient transaction for Lifeward shareholders. Through the equity-based acquisition of Oratech, we gained access to the protein oral delivery platform, a potentially transformative technology across many therapeutic indications, including ORMD-0801 oral insulin, which is expected to commence a Phase II study. Importantly, the clinical program management responsibilities remain with Oramed, utilizing funds previously transferred to Oratech as part of the strategic transaction. That means Lifeward and our shareholders by owning the protein orally delivered platform outright effectively receive a meaningful option on the potential success of the promising technology with minimal near-term operational burden, no material increase in operating expenses and limited management bandwidth requirements beyond my own involvement, supporting strategic oversight and development guidance. As many of you know, my background includes extensive experience in diabetes and metabolic disease, and I believe this platform has meaningful long-term potential. At the same time, Lifeward's core focus remains firmly centered on scaling our neurorehabilitation MedTech business. The second key takeaway from the quarter is Lifeward is now substantially better positioned on its path to profitability. With the $10 million from our convertible note financing, we have significantly strengthened our balance sheet and improved our operating flexibility. This allows us to stabilize and build upon the fundamental and foundational work we have done over the last several quarters, while maintaining our disciplined focus on operational efficiency, market access and innovation across our neuro rehabilitation platform. We expect continued operational stabilization over the next several quarters as our baseline resets following our manufacturing transition initiatives completed over the last year and the consummation of the important transaction this quarter. This gives us improved visibility as we move toward the end of 2026 and into 2027. Turning to commercialization. We continue to make progress expanding distribution in the U.S. and internationally as well as broadening reimbursement access for ReWalk, including through Medicare Advantage insurers such as Aetna, Humana and UnitedHealthcare. We believe this positions our entire neurorehabilitation portfolio and ReWalk in particular, for very long-term growth. On the commercial side, ReWalk's personal exoskeleton sales increased 11% year-over-year, reflecting the continued uptrend we are seeing in international sales, reimbursement and distribution expansion. Total revenue for the quarter was impacted primarily by the AlterG shipment. We experienced temporary timing disruptions associated with working capital constraints late last year that affected sourcing and supply chain execution. Importantly, we have a backlog of secured AlterG orders in place now and have visibility to improve shipment execution during the second and third quarters as we ship against those orders. We are also impacted by tariffs and the financial impacts of our manufacturing transition following the closure of our Fremont, California facility and the shift to contract manufacturing in Massachusetts. Finally, we continue to evaluate strategic and accretive acquisition opportunities that complement our core rehabilitation and biomedical platform. During the first quarter, we acquired an upper body exoskeleton technology designed to address the substantial unmet need of approximately 4.6 million stroke survivors. This is a great complement to our ReWalk platform. Development work is underway as we work towards commercial launch. Overall, we believe Lifeward is stronger strategically and operationally than it was a year ago. We are building a scalable platform with improving operational leverage and multiple potential drivers for future growth. With that, I'll turn the call back over to Almog. Almog Adar: Thank you, Mark. Revenue for the first quarter of 2026 was $3.9 million compared to $5 million in the first quarter of 2025. The year-over-year decline was primarily driven by lower AlterG shipments resulting from temporary supply chain and sourcing constraints associated with working capital limitations and the final stage of our manufacturing transition activities. Importantly, ReWalk personal exoskeleton revenue increased 11% year-over-year to $1.6 million, reflecting continued progress in reimbursement coverage, channel expansion and international sales. Gross margin for the quarter was 34.2% compared to 42.2% in the prior year quarter. The decrease was primarily attributable to lower manufacturing absorption resulting from reduced production volumes, higher freight and tariff expenses as well as unfavorable foreign currency exchange rate movements. Despite lower revenue, we continue to make meaningful progress in improving our operating expenses structure. Total operating expenses were $11.7 million, an increase primarily due to a onetime noncash research and development expense of approximately $4.9 million related to the acquired intellectual property assets in connection with Oratech transaction. On a non-GAAP basis, adjusted operating expenses declined 12% to $5.9 million compared to $6.8 million in the first quarter of 2025. The reduction was driven primarily by improved productivity across sales and marketing operations, lower reimbursement-related costs and reduced R&D spending following the completion of several major development programs. We believe these actions are creating a more efficient operating platforms capable of generating meaningful leverage as revenue volumes increase. GAAP operating loss increased for the quarter to $10.3 million, primarily due to the Oratech-related onetime expenses I just described. On a non-GAAP basis, adjusted operating loss was unchanged year-over-year at $4.6 million despite lower revenue, reflecting the benefits of our cost optimization initiatives. Cash used in operating activities declined by 33% to $3.7 million compared to the first quarter of 2025, primarily reflecting improved operational efficiencies and working capital management. Turning to liquidity. We ended the quarter with $11.4 million in unrestricted cash and cash equivalents compared to $2.2 million at the year-end 2025. The increase reflects the successful closing of our strategic transaction, including the $10 million financing and the additional approximately $6.5 million of cash associated with the Oratech acquisition. As we move through 2026, our focus remains on disciplined cash management, improving operational efficiency and positioning the business for scalable growth and long-term profitability. With that, we will now open the call for Q&A, followed by closing remarks from Mark. Operator: [Operator Instructions] The first question comes from Dr. Yale Jen with Laidlaw & Company. Yale Jen: My first one is that in terms of AlterG, we understand the first quarter figure was due to the timing of shipments. So should we anticipate for the second and third quarter, you will get back to the level similar to last year and sort of make up for the differences? And then I have a follow-up. William Grant: Yale, I think that's a fair assumption. And I think it is going to bridge across the second and third quarter. Yale Jen: So that -- okay. So maybe just on top of that question, on the last earnings call, you guys suggest that the 2026 total revenue will be similar to 2025. And given a little bit lower first quarter figures this year, should we anticipate additional growth in the remaining 3 quarters, again, to match up to the total revenue similar to last year? William Grant: I think some of the things that most people don't appreciate, and we probably didn't explain well is we had a manufacturing move from Fremont to Massachusetts. We also had a complete facility move within Massachusetts, and we started a contract manufacturer all at the same time. And so all of these things led, with our cash constraints, to timing issues on everything. I would expect that we have similar to last year. And I would also expect the exit trajectory to be better than it is the entry trajectory. Yale Jen: Okay. Great. That's very helpful. Maybe the last question here is the ReWalk units in Germany -- the leap in Germany, maybe also in the United States. Could you give a little bit color on both of those? Almog Adar: So the revenues in Germany specifically increased almost 25% quarter versus quarter in ReWalk. And in total, the increase is 11% year-over-year or for ReWalk revenues, we ended with $1.6 million compared to $1.3 million in prior year quarter. Operator: The next question comes from Dr. Ram with H.C. Wainwright. Swayampakula Ramakanth: This is RK from H.C. Wainwright. A couple of questions from me, Mark and Almog. Just trying to understand the AlterG supply/working capital issue. What's the nature of that? And do you think you have already resolved it? Or do you feel you can get it resolved soon so that the flow of product into the market during Q2 and Q3 is going to be smooth. And additionally, I'm not sure you stated this in the call, is there a book of sales that you can give us so that we understand what is expected over the next couple of quarters? William Grant: Yes. So I'll address the first part. I'll let Almog pick up the second part. So by and large, we're going to resolve the issues with AlterG as we go through and exit this quarter. Those were -- RK, those are basically and really relegated to the cash constraints and procurement as we pushed into this quarter. And so it's a timing issue for us. As we stated, we have a backlog of AlterG sales that we're working through today, and we expect those sales to gain momentum as we exit the quarter and move into Q3. But I will caution everybody, I don't believe I'm going to resolve everything this quarter. I think that we'll actually probably carry some into next quarter. But during Q3, we could become whole and be in really good shape. And as far as the outlook -- and again, Almog can give some color on. As far as the outlook, we're going to continue to hold that revenues will be similar to last year, and you could see the trajectory change as we exit the year. But this has been a substantial restructuring of the company, moving to the new strategic partner, changing facilities. And as we get through this lift and start to really mature things, we'll start to give a forward-looking forecast. But right now, we're going to hold. Almog, anything to add? Almog Adar: No, nothing special. At this stage, as Mark mentioned, we are not providing this year guidance, but we're expecting that to be similar to previous year and to do some catch up in Q1. Swayampakula Ramakanth: Okay. Great. And then on the gross margin decline of 800 bps, how much of that is tariff versus FX versus either volume or absorption? Almog Adar: It's a good question, RK. Like -- the fluctuation in the exchange rate together with the tariff, it covered like between 75% to 85% from this gap compared to prior year quarter. The other is mainly the absorption that we mentioned related to the production reduction. Swayampakula Ramakanth: Okay. A couple more questions from me, sorry. On the Medicare Advantage coverage that you have from Aetna, Humana and UnitedHealthcare, is there a way you can give us additional commentary regarding what's the traditional Medicare and what's the conversion rate that you're seeing, especially on submitted claims? William Grant: So when I came into the business, I did an assessment of the business and part of that assessment was actually looking at moving products into the payer landscape and what it takes. If I look back over the innovation trail of Lifeward, they did a phenomenal job of innovation, where they actually had some gaps were how they address payers. And you know the story over the last 3 years where they really started working with Medicare to gain coding, to gain pricing and then now we've started to get coverage and payer placement across other payers. We have a team in the background that's been working with us since I joined the company to assess the situation and to build it since now you've seen Aetna, United and Humana come on board, and our pipeline continues to grow. We need to push further into the private placement into the market, the blues of the world, if you will. And so that pipeline continues to build. Part of the structure is that we're moving to our channel partners, which we announced like Verita Neuro, who have deeper transitions into payers. And so my goal is to get to every patient everywhere in 2 forms, one of which is through their payer and secondarily is to get to them in the community. And so you're asking a great question. This is a piece of the business that has great overlap with my past and that we're building on today. I don't have a direct answer for the pipeline right now as we continue to shift that pipeline from us to our channel partners and continue to build out the distribution network. But there's a lot more to come on this. It's probably the most exciting piece about the business outside of innovation. Swayampakula Ramakanth: And talking about shifting the pipeline, not only you have the products from Oratech, but now you also have an upper body exoskeleton product, which you brought onto your portfolio. So since there are quite a few moving parts, how are you managing your resources and also navigating through all these changes? And you yourself are kind of getting settled into this. So I'm just trying to understand what's the trajectory of things? How should we think about growth from here? And is this a 2-year plan? Or is this a 5-year plan? William Grant: So I think a couple of things, one of which is everybody is going to understand that I've got 3 decades of actually managing these particular revenue cycles. So they're very comfortable to me. Number two, and just to redescribe the Oratech transaction. So there is little to no interaction from our staff with what needs to happen with ORMD-0801 oral insulin. That's going to be handled with Oramed and also is prefunded. And so I'm the only one who actually has overlap with that from a strategic perspective, so it doesn't have any drain on resources. So that's one thing that's really exciting. As we bring in the new upper body exoskeleton, and I'm glad you mentioned that, and we start to work against commercialization and finalizing MVP and bringing that to market, that -- you're going to find that we're going to be known as an innovator, an aggregator and an exploiter of commercial models, right? And those, in particular, are channel partners. We're looking for partners and have partners secured that have these patients at hand. Going out and finding these patients one by one, the needle in the haystack, is definitely not a good business model, and that's why we've made the conscious shift. We're going to work with channel partners that excel in these areas like the CorLifes of the world. We work with workers' comp, where they have these patients at hand, they can market to them and it's a complementary therapy. You could expect the same for all of our portfolio. That's where the vast amount of my experience was spent, was developing channel partners, driving innovation and execution and then obviously, the payer landscape with my background. So those shifts are super exciting and needed for the company. But going to areas where we actually can get to patients directly with channel partners is probably one of the most important things to me going forward. Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Mark Grant for any closing remarks. William Grant: Drew, thank you. Listen, we believe that Lifeward is entering into a new phase as more diversified biomedical innovation company with improving financial flexibility and a clear path for profitability. We remain focused on executing our operational priorities, scaling our neurorehabilitation platform and advancing strategic partnerships while fostering a unique and potentially very high-value event with our biomedical platform. Thank you again for joining us today. We look forward to updating you on our progress next quarter. Thank you, everybody. Operator: The conference has now concluded. Thank you for attending today's presentation. You may now disconnect. Before you buy stock in Lifeward, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Lifeward wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $468,861!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,445,212!* Now, it’s worth noting Stock Advisor’s total average return is 1,013% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of May 15, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Lifeward (LFWD) Q1 2026 Earnings Transcript was originally published by The Motley Fool

Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in operating expenses and cash utilization as company prepares to scale neurorehabilitation products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced its financial results for the first quarter ended March 31, 2026 and that it will delay filing of its Form 10-Q for the quarter ended March 31, 2026 as additional time is needed to finalize the accounting and financial reporting related to the strategic transaction completed in March 2026. “During the first quarter, we significantly strengthened Lifeward’s strategic and financial position through the successful closing of our strategic transaction and financing, marking an important milestone in our evolution,” said Mark Grant, CEO of Lifeward. “With the additional capital added to our balance sheet, the acquisition of Oratech and its Protein Oral Delivery platform, and continued improvements in operating efficiency and cash utilization, we believe Lifeward is now better positioned on its path toward profitability. As we continue to build and grow our solid foundation in neurorehabilitation medtech, our shareholders also have a meaningful opportunity through our Protein Oral Delivery biomed platform.” Recent Corporate Highlights Strategic transaction closed with equity-based acquisition of Oratech: $10 million financing received ORMD-0801 oral insulin Phase 2 trial set to commence: Trial activities to be managed by Oramed utilizing Oratech transaction funds Upper body powered exoskeleton technology addresses unmet need in 4.6 million stroke survivors: The Company entered into an agreement during the first quarter of 2026 to acquire technology with integrated AI capabilities designed to assist individuals with upper-limb mobility limitations ReWalk personal exoskeleton sales increase: Driven by expanding distribution, international sales, and reimbursement coverage from the three largest Medicare Advantage insurers - Aetna, Humana, and UnitedHealthcare First Quarter 2026 Financial Results Revenue was $3.9 million in the first quarter of 2026, compared to $5.0 million in the first quarter of 2025, a decrease of $1.1 million, or approximately 22%. Revenue from the sale of ReWalk Personal exoskeletons increased by 11% to $1.6 million in first quarter of 2026 compared to the same period in 2025. MyoCycle FES bike sales were $0.2 million, unchanged from the first quarter of 2025. Revenue from the sale of AlterG products and services was $2.1 million, a decline of 38% from the same period in 2025. This was primarily due to lower unit shipments in the U.S. and internationally mainly caused by timing issues associated with working capital constraints impacting sourcing and supply chain. Lifeward expects to ship against secured orders during the second and third quarters of 2026. Gross margin was 34.2% during the first quarter of 2026, compared to 42.2% in the first quarter of 2025. The year-over-year decrease was primarily driven by lower production volumes and the resulting reduced absorption of fixed manufacturing overhead, as well as higher tariffs and fluctuations in foreign exchange rates. On a non-GAAP basis, adjusted gross margin was 34.3% during the first quarter of 2026, compared to 42.2% in the prior-year quarter. Total operating expenses in the first quarter of 2026 were $11.7 million, compared to $7.0 million in the first quarter of 2025. The increase was primarily attributable to a one-time, non-cash research and development expense of approximately $4.9 million related to the acquired in-process research and development assets in connection with the Oratech transaction. Excluding this one-time charge, operating expenses decreased year-over-year, primarily reflecting lower sales and marketing expenses and improved operating efficiencies. On a non-GAAP basis, which excludes the items listed in the attached non-GAAP reconciliation table, adjusted operating expenses declined by 12% to $5.9 million in the first quarter of 2026, compared to $6.8 million in the first quarter of 2025. This decrease primarily reflects improved productivity in marketing and sales operations, and lower R&D spending after the completion of major development programs. The Company expects this positive trend in marketing and sales efficiencies to continue into 2026, as it increases investments in R&D to advance new products to market. Operating loss in the first quarter of 2026 was $10.3 million, compared to $4.9 million in the first quarter of 2025, an increase of 113%, primarily due to the items discussed above, including transaction-related and other one-time expenses. On a non-GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted operating loss was $4.6 million in the first quarter of 2026, unchanged from $4.6 million in the first quarter of 2025. Net loss was $10.8 million, or $6.70 per share, in the first quarter of 2026, compared to $4.8 million, or $5.53 per share, in the first quarter of 2025. The increase was primarily attributable to the items discussed above, including transaction-related and other one-time expenses. On a non-GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted net loss was $5.1 million, or $3.13 per share, in the first quarter of 2026, compared to $4.6 million, or $5.28 per share, in the first quarter of 2025. Liquidity As of March 31, 2026, Lifeward had $11.4 million in unrestricted cash and cash equivalents on its balance sheet, compared to $2.2 million as of December 31, 2025. The increase in cash was primarily driven by net proceeds from the convertible notes financing transaction, as well as approximately $6.5 million of cash acquired in connection with the Oratech transaction. Cash used in operating activities during the first quarter of 2026 declined to $3.7 million, compared to $5.5 million during the first quarter of 2025, primarily reflecting improved operational efficiencies and working capital management. Conference Call Lifeward management will host its conference call as follows: Date: May 15, 2026 Time: 8:30 AM EDT Telephone: U.S: 1-833-316-0561 International: 1-412-317-0690 Germany: 0800-6647650 Israel: 1-80-9212373 Access code: Please reference the “Lifeward Earnings Call” The conference call will be webcast live and can be accessed through a link on the Company’s website at golifeward.com in the "Investors" section, or through the following link: https://edge.media-server.com/mmc/p/rz8f7ck8. An archived webcast will also be available on the Company's website at the Investor Events Calendar page. About Lifeward Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton, AlterG® Anti-Gravity system, MyoCycle® FES System, and ReStore® Exo-Suit. These solutions span the continuum of care in physical rehabilitation and recovery, deploying the most advanced robotics and AI technologies to restore full health and quality of life to a broadening patient population. The Company is now executing a strategic evolution into a diversified biomedical company, expanding beyond rehabilitation and into high-value therapeutic platforms. This includes its Protein Oral Delivery (POD™) platform, designed to enable oral delivery of biologic drugs, with lead candidate ORMD-0801 (oral insulin) targeting a large and underserved diabetes market. Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com. Lifeward®, ReWalk®, ReStore® and AlterG® are registered trademarks of Lifeward Ltd. and/or its affiliates. Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: management’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the future operations of Lifeward, including research and development activities; the nature, strategy and focus of Lifeward; Lifeward’s ability to successfully integrate Oratech into its organization and realize the anticipated benefits therefrom; anticipated clinical drug development activities and related timelines, and other clinical results; the sufficiency of post-transaction resources to support the advancement of Lifeward’s pipeline through certain milestones and the time period over which Lifeward’s post-transaction capital resources will be sufficient to fund its anticipated operations; unexpected costs, charges or expenses resulting from the strategic transaction; expected timing and results of the ORMD-0801 clinical trial; legislative, regulatory, political and economic developments; the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company’s ability to continue to operate as a going concern; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2025 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. Non-GAAP Financial Measures To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), the Company believes that the use of non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers to as non-GAAP financial measures, are not prepared in accordance with GAAP. Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, the Company believes that providing non-GAAP financial measures that exclude non-cash share-based compensation expense and acquisition costs allows for more meaningful comparisons between operating results from period to period. Each of the Company’s non-GAAP financial measures is an important tool for financial and operational decision-making and for the Company’s evaluation of its operating results over different periods of time. The non-GAAP financial data are not measures of the Company’s financial performance under U.S. GAAP and should not be considered as alternatives to operating loss or net loss or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in Lifeward’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on the Company’s reported financial results. Further, share-based compensation expense has been, and will continue for the foreseeable future, to be a significant recurring expense in the Company’s business and an important part of the compensation provided to its employees. The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Lifeward urges investors to review the reconciliation of the Company’s non-GAAP financial measures to the comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate the Company’s business. Almog Adar Chief Financial Officer Lifeward E: [email protected] E: [email protected]

HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026. Following the news release, Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: The conference call will be webcast live and can be accessed through a link on the Company’s website at golifeward.com in the "Investors" section, or through the following link: https://edge.media-server.com/mmc/p/rz8f7ck8. An archived webcast will also be available on the Company's website at the Investor Events Calendar page. About Lifeward Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton, AlterG® Anti-Gravity system, MyoCycle® FES System, and ReStore® Exo-Suit. These solutions span the continuum of care in physical rehabilitation and recovery, deploying the most advanced robotics and AI technologies to restore full health and quality of life to a broadening patient population. The Company is now executing a strategic evolution into a diversified biomedical company, expanding beyond rehabilitation and into high-value therapeutic platforms. This includes its Protein Oral Delivery (POD™) platform, designed to enable oral delivery of biologic drugs, with lead candidate ORMD-0801 (oral insulin) targeting a large and underserved diabetes market. Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com. Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates. Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934 concerning Lifeward, Oramed, the strategic investment and partnership agreement with Oramed (collectively, the “Transactions”) and other matters. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: Lifeward’s management team’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the perceived benefits or opportunities of the Transactions; expectations regarding the use of proceeds; the future operations of Lifeward, including research and development activities; the nature, strategy and focus of Lifeward; anticipated clinical drug development activities and related timelines, and other clinical results; the sufficiency of post-transaction resources to support the advancement of Lifeward’s pipeline through certain milestones and the time period over which Lifeward’s post-transaction capital resources will be sufficient to fund its anticipated operations; unexpected costs, charges or expenses resulting from the Transactions; potential adverse reactions or changes to business relationships resulting from the Transactions; and legislative, regulatory, political and economic developments; the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2025 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. Contact: Almog Adar Chief Financial Officer Lifeward E: [email protected] E: [email protected]

This article first appeared on GuruFocus. Release Date: March 18, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Lifeward Ltd (NASDAQ:LFWD) is executing a strategy to become a leading diversified biomedical innovation company with multiple technology platforms. The strategic transaction with Oomed provides meaningful access to capital, strengthening LFWD's financial foundation. The acquisition of intellectual property from Scalable is expected to be highly accretive and supports the development of advanced rehabilitation technologies. LFWD achieved reimbursement coverage for Rewalk with major Medicare Advantage insurers, expanding patient access. The company is making significant progress in international distribution, particularly in Europe, with promising market opportunities. Revenue for the year decreased by approximately 14% compared to the previous year, indicating financial challenges. The transition to a hybrid sales model in the U.S. has not yet translated into immediate revenue growth. A decline in Ultra G sales due to distributor dynamics created a year-over-year comparison headwind. Operating expenses remain high, although they have decreased, impacting overall profitability. The company is not providing guidance at this time due to ongoing strategic transformations, creating uncertainty for investors. Warning! GuruFocus has detected 4 Warning Signs with LFWD. Is LFWD fairly valued? Test your thesis with our free DCF calculator. Q: How does the focus on oral insulin technology align with Lifeward's commercial infrastructure, and what work is needed for approval? A: Mark Grant, CEO: The alignment will be clearer post-transaction closure. With my extensive experience in the metabolic space, this technology fits well into our diversified portfolio. It allows us to transition from a centralized to a decentralized commercial model, enhancing our innovation capabilities. The work needed for approval will be determined as we progress, but the acquisition is fully funded, allowing us to focus on our core business while expanding opportunities with Oramed. Q: What is the timeline for the upper extremity robotic assistance product, and how does it complement the Rewalk system? A: Mark Grant, CEO: We anticipate a 12 to 24-month timeline for development. The product is likely to be a 510k exempt, meaning low barriers to entry. While specific clinical studies are not yet outlined, they will likely focus on safety and efficacy. This product complements our Rewalk system by expanding our neurorehabilitation offerings. Q: How should investors view Lifeward's strategy of expanding into biotech and upper extremity robotics? A: Mark Grant, CEO: Our strategy is to evolve into an innovation company that understands market channels, regardless of whether the product is biotech or medtech. We aim to leverage our experience in commercialization and reimbursement to exploit these opportunities, creating a diversified and durable portfolio that can weather market changes. Q: What drove the unexpected revenue performance, and what should be expected in 2026 and beyond? A: Mark Grant, CEO: We view Lifeward as a startup in terms of commercialization and reimbursement pathways. We've integrated these into our operations, improving payer and global coverage. While we're not fully there yet, we expect to maximize coverage in the next 12 to 18 months. Our focus is on building a strong foundation for future growth. Q: Can you quantify the backlog for Medicare beneficiaries as you enter 2026? A: Mark Grant, CEO: While we don't have exact numbers, the 22% year-over-year growth in units sold is promising. Our reimbursement coverage is expanding, which is increasing our pipeline. We expect this growth to continue into the next quarters. For the complete transcript of the earnings call, please refer to the full earnings call transcript.